Abstract | PURPOSE: A Phase I U.S. FDA clinical study of a plate haptic posterior chamber phakic intraocular lens (STAAR Surgical Implantable Contact Lens) for treatment of hyperopia was conducted at 4 sites in the United States. The purpose of this report is to assess the short-term safety and efficacy. METHODS: Ten patients with hyperopia between +2.50 and +10.875 D were implanted in one eye each with the posterior chamber plate phakic intraocular lens and were examined at baseline and 1 day, 1 week, 1, 3, and 6 months after surgery. Mean baseline hyperopia was +6.63 D. RESULTS: At 6 months postoperatively, 7 of 10 eyes (70%) had an uncorrected visual acuity of 20/20 or better and 10 of 10 (100%) had 20/40 or better. Eight of ten eyes (80%) had a spectacle-corrected visual acuity within 1 line of baseline; the other two eyes (20%) had an improvement of 3 lines. Mean 6-month postoperative spherical equivalent refraction was +0.20 +/- 0.61D (range, -0.50 to +1.50 D), a reduction of 6.025 D from baseline. Eight of 10 eyes (80%) were within +/-0.50 D of emmetropia, 9 eyes (90%) were within +/-1.00 D, and all eyes (100%) were within +/-1.50 D. No operative or postoperative complications or adverse reactions were observed. CONCLUSIONS:
|
Authors | D R Sanders, R G Martin, D C Brown, J Shepherd, M R Deitz, M DeLuca |
Journal | Journal of refractive surgery (Thorofare, N.J. : 1995)
(J Refract Surg)
1999 May-Jun
Vol. 15
Issue 3
Pg. 309-15
ISSN: 1081-597X [Print] United States |
PMID | 10367572
(Publication Type: Clinical Trial, Clinical Trial, Phase I, Journal Article, Multicenter Study)
|
Chemical References |
- Biocompatible Materials
- Methacrylates
- hydroxyethyl methacrylate
|
Topics |
- Adult
- Biocompatible Materials
- Follow-Up Studies
- Humans
- Hyperopia
(surgery)
- Lens Implantation, Intraocular
- Lens, Crystalline
- Lenses, Intraocular
- Methacrylates
- Middle Aged
- Refraction, Ocular
- Safety
- Treatment Outcome
- Visual Acuity
|